F2RL1 and neoplasm: Several mechanisms of action are considered for tisotumab vedotin-tftv: (i) MMAE-mediated cell cycle arrest and apoptosis of both tumor and bystander cells and induction of immune cell death; (ii) Fc receptor-mediated effector, including antibody-dependent cellular toxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP); and (iii) antigen-binding fragment-mediated inhibition of protease-activated receptor-2 (PAR-2)-dependent signaling [59].